Wyeth, Solvay Schizophrenia Drug Has Favorable Safety Profile
Posted on: Friday, 30 March 2007, 12:00 CDT
Wyeth Pharmaceuticals has said that new research conducted on its schizophrenia drug bifeprunox shows that it has a favorable side effect profile.
Many current schizophrenia drugs induce weight gain but safety analysis of bifeprunox suggests it is associated with a favorable weight and lipid profile. In addition the analysis showed increases in weight occurred in patients receiving active references versus placebo. Bifeprunox was discovered by Solvay Pharmaceuticals and is being developed by Wyeth, Solvay and Lundbeck.
"Data from phase II and phase III trials suggest that, if approved, bifeprunox may be an important treatment option for stable patients with schizophrenia - particularly because of our concerns about the high prevalence of metabolic syndrome in this patient population," said Herbert Meltzer, director of the Division of Psychopharmacology, Vanderbilt University Medical Center.
In October 2006, Wyeth Pharmaceuticals and Solvay Pharmaceuticals reported that a new drug application was submitted to the FDA for bifeprunox.
Under a new agreement announced in January 2007, Wyeth and Solvay will collaborate in a joint discovery effort targeting the identification of small molecules as potential antipsychotic medications.
Source: Datamonitor
Related Articles
- Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
- Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
- Wyeth Pharmaceuticals Introduces New Hemophilia Drug
- Crucell Announces Vaccine Development Agreement With Wyeth Pharmaceuticals
- Solvay Pharmaceuticals, Inc. And Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
- Solvay/Wyeth Drug Controls Schizophrenia
- Wyeth Pharmaceuticals Announces Scottish Collaboration to Enhance Translational Medicine Research
- Emilio A. Emini, Ph.D., Appointed Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals
 |
 |
User Comments (0)
RSS Feeds